Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2000

View Archived Issues

Amylin reports phase II results for synthetic exendin-4

WAY-160910 designated a development candidate, triggering payment to Ligand

Alfa Wassermann will market and distribute Ligand's oncology products in Italy

Canstatin is a potent angiogenesis inhibitor in preclinical models

Cell Therapeutics adds late-stage development compound to pipeline

Ribonucleotide reductase R2-targeting antisense oligonucleotides for neoplastic diseases

Hepatotoxicity of HIV protease inhibitors: a real but controllable risk

NCI begins additional trial of Genta's bcl-2 antisense compound

OSI Pharmaceuticals licenses gene transcription patent estate to R.W. Johnson

Strategic alliance formed between Medarex and Kirin Brewery

Serono and Bioject collaborate on needle-free delivery of hGH

Positive preclinical results reported for Maxim's oral mucositis gel

Macrolides synthesized at Pfizer reported to possess broad-spectrum antibacterial activity

Alpha4-selective integrin antagonists in the Celltech pipeline

Almirall Prodesfarma presents new PDE5 inhibitor series

U.S. university researchers design improved trans-platinum complexes

Agouron's new HIV protease inhibitors show nanomolar antiviral activity, low cytotoxicity

Novel ADIR compounds active in vitro and in vivo as antitumor agents

Lipid regulator CI-1027 may also be useful in Alzheimer's disease

Phase III data reported for rhATIII

Naturally and non-naturally occurring cyclic depsidecapeptides synthesized and evaluated at Scripps

Japanese marketing approval no longer sought for Mochida's TNF

New study indicates potential of kappa-opioid receptor agonists in HIV-1 encephalopathy

AstraZeneca enters agreement with Vion/EPTTCO for cancer drug delivery technology

Second pivotal phase III trial of adefovir dipivoxil as HBV treatment initiated

GnRH-based fusion toxin markedly reduces human colon tumor growth in mouse model

Milkhaus receives milestone payment from Elan relating to Alzheimer's agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...